Companion Diagnostics

to those who need it

of laboratory directors see cost savings as a main benefit of PHC2

40% NEARLY

INCREASE in the number of new cancer drugs entering clinical testing4

50%

1993

-199

8

1999

-200

4

MILLIONannual cost savings for the US health care system if patients with metastatic colorectal cancer receive a genetic test prior to treatment3

740

of pathologists see better response rates & successful outcomes with targeted therapies2

44%

for targeted diagnostics & therapies1

72personalized optionsavailable*

deliver Personalized Healthcare

1. Personalized Medicine Is Playing a Growing Role in Development Pipelines: Tufts Center for the Study of Drug Development. Impact Report, 12 (November/December 2010): 6 http://csdd.tufts.edu/files/uploads/nov-dec_ir_report_summary.pdf

2. Personalised Healthcare Perception Study – Laboratory heads, Summary of key findings 8 April 2014, Ebiquity Research, UK3. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies D. Soulières, W. Greer, Anthony M. Magliocco,

D. Huntsman, S. Young, M.-S. Tsao, S. Kamel-Reid Curr Oncol. 2010 July; 17 (Suppl 1): S31–S40. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901795/4. Clinical success rates for new cancer drugs double while more enter testing. Tufts Center for the Study of Drug Development. Impact Report, 15 (May/

June 2013) 3 http://csdd.tufts.edu/files/uploads/may-jun_2013_ir_summary.pdf

*As of 2011

Path

olog

ists

Labs

Patie

nts

Onc

olog

ists

Soci

ety

© 2014 Ventana Medical Systems, Inc. VENTANA and the VENTANA logo are trademarks of Roche. All other trademarks are the property of their respective owners. Web5258 0514A